Arbutus Biopharma Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$252.8Mnext fiscal year
FY EPS (est.)
$1.03next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Functional Cure Rate in HBeAg-negative cHBV Patients (baseline HBsAg < 1000 IU/mL) Quarterly50.0%Target: Maintain high efficacy rates in larger cohorts
Total Phase 2a Patients Achieving Functional Cure Quarterly10.0Target: Demonstrate incremental cures in long-term follow-up
Percentage of Phase 2a Patients Discontinuing NA Therapy Quarterly0.5Target: Maximize treatment-free duration
Watch Items
- Moderna Upfront Settlement Payment ReceiptTrigger: $950 million upfront payment due to Genevant/Arbutus in July 2026Action: Confirm receipt of funds and determine exact net allocation to Arbutus (entitled to 20% after litigation costs plus 16% equity stake in Genevant)
- Evaluation of Return of Capital to ShareholdersTrigger: Board decision and announcement in Q3 2026Action: Assess the structure, size, and timing of the capital return following the Moderna upfront payment
- Moderna Section 1498 Appellate RulingTrigger: Federal Circuit Court of Appeals decision on government-contractor immunityAction: Monitor for potential realization of the contingent $1.3 billion payment within 90 days of a favorable ruling
- Pfizer/BioNTech LNP Patent Litigation ProgressTrigger: Trial milestones or settlement discussions following the favorable September 2025 Markman rulingAction: Track legal developments as Pfizer/BioNTech's Comirnaty represents approximately two-thirds of global COVID-19 mRNA vaccine sales
- Imdusiran Phase 2b Clinical Trial InitiationTrigger: Regulatory approval and first patient dosedAction: Review trial design, enrollment progress, and baseline characteristics of the planned 170-patient cohort
Research as of 19 Jun 2026